


Name: FX-909 cat#: EX-A7772

Target: PPAR

Pathway: Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

Chemical Structure:



Chemical Name	3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile		
---------------	--	--	--

Molecular Weight	360.33	Storage	Powder
Formula	C17H10F2N2O3S		3 years -20°C; 2 years 4°C 6 months -80°C in solvent Away from light
CAS No.	2924573-90-8	Synonyms	FX909; FX 909

Solubility (25°C) *	In vitro	DMSO	>50mg/mL
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)	In Vivo Add each solvent one by one: 1. 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution	

* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual

solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Concentration \ Mass Volume	Mass	1 mg	5 mg	10 mg
	Volume			
1 mM		2.7752 mL	13.8762 mL	27.7523 mL
5 mM		0.5550 mL	2.7752 mL	5.5505 mL
10 mM		0.2775 mL	1.3876 mL	2.7752 mL

DMSO :

*The above data is based on the product molecular weight 360.33.

Biological Activities:

Description	FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist.
IC₅₀ & Target	PPAR γ
In Vivo	FX-909 (0.03-1 mg/kg; BID for 21 days) shows anticancer effects in UMUC9 UC xenograft mouse model.

References	[1]. Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7 Supplement): 2802-2802.
-------------------	--